Is compounded semaglutide legal?

FDA determined that the tirzepatide injection shortage was resolved on December 19, 2024, and the semaglutide injection shortage on February 21, 2025. Those determinations removed a shortage-based basis for making copies; they did not erase every other compounding pathway. Availability at one local pharmacy is not the same as a national FDA shortage determination.

The FDA policy update describes transition periods and litigation-related updates. For tirzepatide, the relevant 503A transition date was March 19, 2025, following the court decision, and the 503B period ended March 19, 2025. For semaglutide, the periods ended April 22, 2025, for 503A and May 22, 2025, for 503B. These shortage-related enforcement-discretion periods have ended; they are not a continuing permission to supply routine copies.

Section 503A provides conditional exemptions from certain federal drug requirements. In ordinary patient care, a licensed pharmacy compounds for an identified patient based on a valid prescription. Limited anticipatory compounding can be allowed under statutory conditions, but that does not turn 503A into unrestricted manufacturing for general inventory.

The compounder must also satisfy requirements concerning ingredients and other conditions. A prescription is necessary for the patient-specific pathway, but it does not by itself resolve the essentially-copy restriction. Read the FDA comparison of statutory requirements alongside the current GLP-1 policy, rather than treating a pharmacy’s license as the entire legal analysis.

Under 503A, a compounder must not regularly or in inordinate amounts compound drugs that are essentially copies of commercially available products. FDA considers factors including the active ingredient, a same or similar or easily substitutable strength, and whether the commercial product can be used by the prescribed route.

A relevant exception involves a prescriber determining and documenting that a change produces a significant difference for an identified individual patient. This is a clinical determination, not a marketing phrase. A different price, a patient’s general preference, or a custom-looking label should not be presented as proof that the exception applies.

Not automatically. Join Luma offers a formulation with glycine or vitamin B12 and an additive-free formulation, subject to clinician confirmation and state availability. The fact that an ingredient has been added does not establish that it creates a clinically significant difference for every patient.

FDA’s current guidance specifically addresses combinations and the need for a documented prescriber determination where applicable. Ask what patient-specific medical need the formulation addresses. Do not assume that B12 guarantees more energy, that glycine prevents side effects, or that either additive changes the legal status simply by appearing on a label.

FDA distinguishes semaglutide base from semaglutide sodium and semaglutide acetate. These salt forms are different active ingredients from the one used in approved drugs. FDA has said it is not aware of a lawful basis for their use in compounding under the applicable federal conditions. A listing that merely says semaglutide is not enough to settle which ingredient is present.

The FDA GLP-1 concerns page also warns about products sold for research rather than human treatment. Ask the dispensing pharmacist to confirm the active ingredient and source. Do not buy a research vial to mix or inject yourself, and do not interpret an ingredient supplier’s FDA registration as approval of the finished medication.

Join Luma routes patient-specific prescriptions to U.S.-licensed 503A pharmacies. Hallandale Pharmacy in Fort Lauderdale prepares the additive-free formulation; VialsRx in Tomball, Texas, prepares formulations with glycine or vitamin B12. Patients choose a formulation and the clinician confirms whether it is appropriate. Read the pharmacy partner overview for the practical routing details.

Hallandale’s supplied Florida sterile compounding license number is PH28017. VialsRx’s supplied Texas license number is 35264, Class A-S. State authorization matters both where a pharmacy operates and where it dispenses or ships. Availability can therefore differ by your delivery address; a pharmacy being licensed in its home state is not a universal shipping authorization.

Use the 503A versus 503B guide to understand oversight and the pharmacy-selection checklist to organize your questions.

Ask your clinician why a compounded formulation is appropriate for your medical needs, who will dispense it, and how to contact that pharmacy. Your vial should identify the pharmacy, concentration, directions, and beyond-use date. If a label conflicts with portal instructions, resolve the mismatch before using the medication rather than selecting whichever directions seem familiar.

Compounded drugs are not FDA-approved and are not FDA-approved generics of Wegovy or Ozempic. The FDA compounding questions and answers explains that distinction. This guide describes the regulatory framework, not a legal guarantee for any individual prescription. For current options, review Join Luma injections and discuss the decision with the reviewing clinician.